Athersys, Inc. (ATHX) Sees Large Decrease in Short Interest

Athersys, Inc. (NASDAQ:ATHX) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 1,796,142 shares, a drop of 11.4% from the March 15th total of 2,028,124 shares. Based on an average daily trading volume, of 3,390,838 shares, the short-interest ratio is currently 0.5 days.

Several equities research analysts recently weighed in on ATHX shares. William Blair reiterated an “outperform” rating on shares of Athersys in a research note on Tuesday, March 28th. Maxim Group set a $9.00 target price on shares of Athersys and gave the company a “buy” rating in a research note on Monday, March 20th. Needham & Company LLC started coverage on shares of Athersys in a research note on Tuesday, February 7th. They issued a “buy” rating and a $7.00 target price for the company. Finally, Zacks Investment Research cut shares of Athersys from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 3rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $5.75.

Shares of Athersys (NASDAQ:ATHX) opened at 1.49 on Friday. Athersys has a 1-year low of $1.02 and a 1-year high of $2.60. The company’s market cap is $163.61 million. The company has a 50 day moving average of $1.34 and a 200 day moving average of $1.52.

Athersys (NASDAQ:ATHX) last issued its quarterly earnings results on Thursday, March 9th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.02. Athersys had a negative return on equity of 22.82% and a negative net margin of 17.12%. The firm had revenue of $0.98 million for the quarter, compared to the consensus estimate of $0.45 million. During the same period last year, the company posted $0.04 EPS. The business’s revenue was down 90.7% on a year-over-year basis. Equities analysts expect that Athersys will post ($0.29) earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. NEXT Financial Group Inc increased its stake in shares of Athersys by 14.4% in the third quarter. NEXT Financial Group Inc now owns 106,100 shares of the biopharmaceutical company’s stock worth $226,000 after buying an additional 13,350 shares during the period. State Street Corp increased its stake in shares of Athersys by 1.9% in the fourth quarter. State Street Corp now owns 1,119,590 shares of the biopharmaceutical company’s stock worth $1,714,000 after buying an additional 20,680 shares during the period. Teachers Advisors LLC increased its stake in shares of Athersys by 21.9% in the fourth quarter. Teachers Advisors LLC now owns 156,880 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 28,178 shares during the period. Oxford Asset Management purchased a new stake in shares of Athersys during the fourth quarter worth $105,000. Finally, Prudential PLC increased its stake in shares of Athersys by 8.9% in the fourth quarter. Prudential PLC now owns 2,150,000 shares of the biopharmaceutical company’s stock worth $3,290,000 after buying an additional 175,000 shares during the period. 17.24% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/04/21/athersys-inc-athx-sees-large-decrease-in-short-interest.html.

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

5 Day Chart for NASDAQ:ATHX

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply